Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Our prizes for best papers in the last year have become as eagerly awaited as the Oscars and are much more glamorous. As before, we have awarded GOLD, SILVER and BRONZE prizes in the following categories: paediatrics, adult clinical, basic science and epidemiology. This is the first of two reviews of manuscripts published in Thorax in 2014 dealing with manuscripts on the clinical aspects of paediatrics and adult respiratory medicine. Decisions are purely those of the editors and deputy editors. Our only restriction has been to not consider manuscripts exclusively from Imperial and Oxford because we have conflicts of interest. Next month we deal with basic science and epidemiology manuscripts and reveal the overall winner.
Paediatric year in review
The year 2014 has featured a large number of strong paediatric manuscripts covering the whole range of respiratory medicine, including really important data on the early origins of adult lung disease. Patients with traditional ‘paediatric’ diseases, such as cystic fibrosis (CF) and Duchenne muscular dystrophy are now surviving into adult life, further blurring the barriers between adult and paediatric chest physicians. But nonetheless, this year has re-emphasised that aspects of what appears to be the same disease are different and show developmental changes. We cannot unlock the secrets of disease in children by studying adults.
The early bird gets an unwanted worm: Early life events are of huge importance long term. The Melbourne cohort has run for >40 years; and this year they showed that severe asthma at the age of 10 years is a bigger risk factor for COPD than smoking, at least in their cohort, and furthermore, at age 10 years the COPD adults had the lowest spirometry.1 Interestingly, the rate of decline of lung function did not seem different between the groups. Our editorialists highlight the key importance of optimising lung health early—a message that simply must reach the public domain.2 The Thorax take? If ever there was a demonstration of the futility of the umbrella diagnosis of COPD it is this paper—is non-atopic, smoking-related COPD really the same entity as premature airflow obstruction on a presumed background of previous eosinophilic inflammation?
Good news and bad news: Lung function may track from as early as 1 month of age until age 18 years, but also, as we are appreciating in other contexts, there is scope for some catch-up, especially in some of those who were the victims of maternal smoking in pregnancy.3 As with many observations, the importance is clear, but reversing the abnormalities is more challenging.4 We cannot change parental atopy; but we surely can do more about that old favourite, smoking. How many schoolchildren are taught that smoking may permanently harm your unborn baby (and even your baby's babies, if other studies are to be believed).
We all know that living in a rural community is a GOOD THING, don't we? Well, no—not if you live in Ecuador, where a great study challenged this paradigm.5 It looked like atopy and wheeze, but not rhinitis and eczema, were more common in rural children. The contrast with data from PARSIFAL and elsewhere is stark. These geographical variants must be telling us something, but what? This paper gets our Paediatric SILVER MEDAL, honouring research in testing conditions which challenges comfortable, developed world certainties.
CF—times they are a-changing: CF used to be diagnosed late in often severely symptomatic children, and management strategies were directed at firefighting the downstream consequences of the gene mutation. Now newborn diagnosis of well babies and direct targeting of the primary defect have come to the fore. But what happens after screening—doom and gloom according to the Australian AREST-CF team, with rapidly deteriorating lung function and evolving structural damage. Not so, say LCFC—lung function actually improves over the first year of life,6 and HRCT changes are for the most part too mild to score.7 These two papers are our joint BRONZE MEDAL winners, not just for Science but for hitting back at the Australians after a five zip Ashes whitewash. Despite possessing the Wisdom of Solomon, our editorialist Peter Merkus was unable to resolve this Anglo-Australian controversy.8 The importance is that if AREST-CF is right, novel therapies should be trialled soon; if LCFC, the babies are doing so well that treatment can be deferred. Watch this space.
Ivacaftor directly targets class III mutations, and this year the indication for ivacaftor was extended from G551D to other, rarer gating mutations (another triumph for the clinical trial active CF community—an example to all disease groups). One criterion for acceptance on to the treatment programme is a reduction in sweat chloride (typically by around 50% in the published trials). However, Barry et al9 cast doubt on the wisdom of this by showing that there is no correlation between sweat chloride response and improvement in FEV1. So is CF lung disease really a disease of chloride transport? And if we assume wrongly that it is, will we pass up other promising treatments?
However, among the excitement of new horizons, attention to old problems is still essential. Diagnostic sophistication is ever greater, and confusion can multiply in consequence. The diagnosis of CF may be even harder despite multiple tests, and genetics may actually be the least informative approach, even using the 122 known disease causing mutations (out of around 2000 possible candidate changes in DNA at the CFTR locus).10 Prevention of cross-infection is essential in CF, but coughing spread actually spread Pseudomonas over a 4 m radius, with persistence for 45 min, a considerable challenge to the 1–2 m assumed by current practice.11 The actual practical risk to patients as a result of not changing practice is unclear, but the challenge remains to optimise clinic conditions to reduce risk while maintaining efficiency and actually seeing more than one patient in an afternoon.12 Time and The International Depression Epidemiological Study (TIDES) wait for no man—is depression and anxiety commoner in CF13 or is this paper fundamentally flawed?14 Read both for yourself and watch the correspondence columns with bated breath! CF lung attacks—see Thorax passim (a previous issue for the classical ignoramus) may well lead to a permanent decrement in lung function, are associated with accelerated decline in spirometry and a worse prognosis—and may be predicted by an elevation in lung clearance index (LCI).15 Prediction is one thing, stopping them is another, not addressed—but perhaps we should be using LCI clinically in this way? One barrier to prevention is the fact that many CF lung attacks are related to viral infections, even in adults.16 How badly we need effective and safe antiviral strategies for all-age patients!
The Grim Reaper: (or sickle cell disease (SCD), a big global player in non-infective morbidity and mortality in children). The prevalence of airway disease, usually labelled asthma, is said to be increased. However Chaudry et al17 showed that, although airflow obstruction is common and early in SCD, there is no evidence of airway hyper-responsiveness or inflammation. Whatever this SCD airway disease, it is not conventional asthma—so please, please can we stop using the term? And, is SCD a primary airway not vascular disease? However, vascular abnormalities are clearly significant. Lunt et al18 used HRCT to get a handle on pulmonary vascular volume and suggested that these may relate to some of the lung function abnormalities in SCD including changes over time. Acute chest syndrome in SCD comes in many radiographic forms. Mekontso Dessap et al19 found that consolidation was more severe in the apex and was more prevalent than ground glass change or atelectasis. Its presence was associated with a worse prognosis.
From the Department of Dirty Tricks: Who but the tobacco industry takes pole position here? Nick Hopkinson has a great track record for getting in the face of the industry (no Knighthood for you, Nick!), and he and colleagues looked at the uptake of smoking by children across the country—67 A DAY in London alone.20 What is Government doing (other than procrastinating) in the face of this industry triumph? Taking the tobacco shilling (or a rather larger currency note)? Queen's Awards for Industry and Trebles all round.
Of course there is more to pollution than tobacco, and more to Governmental kid gloves than schmoozing the tobacco industry. Near roadway air pollution adversely affects children's lung function, independent of regional pollution.21 What a surprise! Who would have thought it? Although our editorialists properly urge caution with regard to some of the methodology,22 a question: what is there to be lost by keeping traffic well away from residential areas? And a much more difficult question—why don't politicians break off their thundering tirades about the iniquities of the National Health Service, which seem to persist despite (because of?) the mandarins ‘reforming’ it for quarter of a century with a degree of purpose which make headless chickens look like Einstein, and actually pass legislation that would help children? Answers in a letter to Thorax, please, and beware of low flying pigs!
Severe ‘asthma’ in children: Why are a few children with asthma so difficult to treat, even when prescribed treatment is actually taken and the pet cat disenfranchised? Pollution leads to the accumulation of carbon particles in alveolar macrophages, but there is less carbon in macrophages of children with severe asthma.23 Is this due to impaired macrophage function in these children? The authors speculate that the mechanism may be via elevation in PGE2 in severe asthma. Is the problem a failure of resolution of inflammation? Gupta et al24 showed that BAL interleukin (IL)-10 levels in severe asthma were positively correlated with serum vitamin D levels, and vitamin D enhanced steroid-induced IL-10 production by peripheral blood mononuclear cells. IL-17A was not affected—is it friend or foe in severe asthma? And will vitamin D deliver the goods therapeutically?
Turning the air (or at least the patient) blue: Old fashioned physiology—the anatomical shunt test (the patient breathes 100% oxygen and peripheral arterial saturation is measured at equilibrium) is a good first-line screening test when compared with more sophisticated or invasive tests.25 What about saturation studies in hereditary haemorrhagic telangiectasia (HHT)? This condition may be more common that once thought, with an estimated UK prevalence of at least one in 9500.26 We all learn about orthodeoxia as a diagnostic test, but actually, although possibly useful in examinations and for ward round show-offs, it is not useful in children with HHT.27 Not so in adults; orthodeoxia was common, as was orthostatic tachycardia, which was associated with better exercise tolerance, for reasons that are obscure to this writer.28 Extrapolate across the age spectrum at your (or your patient's) peril.
Going Viral! The dangers of extrapolation, part 2. It has long been suggested that asthmatics have reduced respiratory epithelial cell production of β-interferon (IFN) and λ-IFN in response to viral infections. Not so in young atopic children; they do have a defect in viral clearance, but it is not related to IFN and is virus specific.29 Importantly, responses vary at different levels of the respiratory tract, highlighting the importance of paediatricians actually doing paediatric research, and not being content with low-hanging fruit (in this case, nasal epithelial cells).30
Treatment of viral infections is a big problem. A real light SABRE—nebulised hypertonic saline is recommended as a great treatment for RSV bronchiolitis—and so it is, according to the SABRE study, with one slight problem—it doesn't work!31 Perhaps this study was helped by avoiding the problems of previous work, which used a placebo which made babies worse—always a good way to show benefit for an ineffective intervention. The SABRE group can dance for joy—they win the Paediatric GOLD MEDAL for 2014 for a practice changing, definitive paper in an important field. In this context, Cunningham and Unger32 pointed out the virtues of doing original research, rather than endlessly meta-analysing the work of others, a sentiment with which your editors would certainly agree. If we can't treat bronchiolitis, can we prevent it? Maybe we can if we optimise the management of pregnant women with asthma by measuring exhaled nitric oxide,33 although this finding requires confirmation.
The Best of the Rest: There were a number of important papers which do not fit into the above categories. MDR TB is a real threat—and so it was encouraging to read that >90% of infected children can be treated successfully using an individualised approach.34 With the threat of drug-resistant TB, should we not optimise prevention with BCG?35 Worryingly, one in three high-risk infants did not receive BCG. Time for a change? Anything to be lost from a blanket policy of immunising all babies?
Get it right for children and you'll get it right for adults? Alternatively, never work with children. Pneumococcal community-acquired pneumonia in adults was associated with contact with children, but pneumococcal vaccination of the children had the spin-off of protecting adults.36 So the kids get the pain (of injection), the adults the gain—same for paediatricians and adult physicians, perhaps?
Lastly, silent night or snoring night? Obstructive sleep apnoea (OSA) in children was once so simple, they had fat tonsils, fat bodies or both. Tan et al37 discussed the much greater complexities of phenotyping paediatric OSA in the modern era, in a mind-stretching review.
And finally: never work with children or animals! So the finale is the report showing that racehorses with Heaves, a better biological model than mice although rather more demanding to work with, have an altered smooth muscle heavy chain isoform which is reversed by inhaled steroids.38 A special Thorax prize for the most ingenious medication delivery device, provided it is actually demonstrated while riding a Heaving Horse!
Adult clinical year in review
Marking time? 2014 has been a good year for biomarker research, with a number of contenders for our prestigious 2014 BIOMARKER OF THE YEAR AWARD. Encouragingly an increasing number of manuscripts describe biomarkers that are associated with clinically important outcomes and identify treatment opportunities. The sputum-serum hydrogen sulfide ratio looks like a robust and measureable biomarker of neutrophilic airway inflammation in patients with COPD,39 potentially a clinically important pattern of airway inflammation. More compellingly, a blood thrombocytosis was found to be associated with increased mortality in patients hospitalised with a COPD lung attack.40 This effect was seemingly independent of cardiovascular mortality and was not present in patients taking antiplatelet agents, elevating the findings into the potentially clinically very important category. For this reason, and because the biomarker count is routinely measured, the blood platelet count wins our biomarker of the year award. Serum and pleural fluid fibulin 3 and mesothelin had less good years, winning the ‘nice try, pity about the data’ award. Creaney et al41 showed that these molecules performed significantly less well as diagnostic and prognostic markers in malignant mesothelioma than earlier studies had suggested, emphasising the importance of validation studies. Hellyer et al42 performed an excellent biomarker discovery and validation study in patients with ventilator-associated pneumonia, finding that low serum IL-1b and IL-8 effectively excluded this condition. Finally, 3He MRI demonstrated that ventilator defects were seen in the patients with more severe asthma studied by Svenningsen et al.43 Whether these defects identify airways that could be usefully treated with bronchial thermoplasty is a key remaining question.
We also had several strong papers describing new outcome measures or further validating existing instruments. The ultimate outcome measure is to visualise the pathological process directly in vivo. Cosio et al,44 in our SILVER MEDAL paper in this category, show that this might be possible in patients with COPD using a standard broncoscopy and fibred confocal florescence microscopy. Patient reported outcome measures are also much to the fore. The clinical COPD questionnaire looks like a simple, quick to measure quality of life questionnaire with a bigger effect size following pulmonary rehabilitation that other, more cumbersome but better known instruments.45 Many of our patients with COPD find themselves attending for a CT chest and the number will increase with lung cancer screening. The presence of coronary artery calcification was found to be associated with increased COPD-associated symptoms and mortality and evidence of increased systemic inflammation.46
Will your editors score? Other new outcome measures including a new symptom scale for patients with COPD suitable for daily use;47 a scoring system capable of predicting survival in patients with malignant pleural effusions;48 a lung-transplant specific quality of life score49 and an ultrasonic technique for assessing diaphragmatic thickness and likelihood of successful weaning in patients requiring mechanical ventilation.50 The radiographic pattern of connective tissue disease-associated interstitial lung disease was shown to be heterogeneous by Saketkoo et al51 Understanding this heterogeneity is a priority before progress can be made with treatment, as is the identification of potential outcome measures. Saketkoo et al51 provide an excellent evaluation of the likely candidates.
Trials and tribulations? Once armed with the right outcome measures and biomarker of the pathogenic process, the clinician is in a strong position to carry out the killer clinical trial. We had a particularly strong crop of these in 2014.52–60 The pick of these, and the winners of our BRONZE and GOLD MEDALS in this category, are two large, definitive trials with surprising findings (always the best sort of clinical trial). The BRONZE MEDAL winner61 found that inhaled mannitol, previously shown to be beneficial in patients with CF, had no effect on exacerbations of non-CF bronchiectasis. This finding together with earlier similar findings with inhaled DNAse emphasises that CF and bronchiectasis are very different. The GOLD MEDAL winner by Struik et al62 investigated the effect of nocturnal non-invasive ventilation following a hospital admission with a COPD lung attack and persistent hypercapnoea. Treatment reduced nocturnal and day time pCO2 but had no effect on readmission rates or death. Congratulations to the authors for carrying out a demanding and clinically very important study.
Your editors are perhaps not alone in finding the process of meta-analysis (ie, picking over the bones of other peoples hard work until a striking but highly unlikely finding emerges) hugely overrated as a means for identifying clinically important effects. We published three such analyses in 2014, both a cut well above the usual. Yu et al63 performed an analysis of FDA data on the effects of roflumilast in COPD, finding a 0% probability of benefit across different categories of patients but a 50% probability of a >22% reduction in COPD lung attacks in patients with a prior history of >1 attack in the last year; lung attacks as important are an ongoing theme. Bratton et al64 carried out a meta-analysis of individual data from trials of CPAP treatment in minimally symptomatic OSA. They found no evidence that CPAP reduced blood pressure in the whole population, although it did result in symptomatic benefit. There was a small but significant effect on blood pressure in the subgroup who used CPAP for >4 h. Finally, Gimeno-Santos et al65 were largely unsuccessful in identifying determinants of physical activity in patients with COPD despite performing an exhaustive analysis of 86 studies.
In contrast, observational studies, particularly those from highly expert and busy centres, are a greatly underrated form of medical evidence. A good example is the study by Bridevaux et al66 investigating viral infections in lung transplant recipients. These occurred frequently, commonly involved Picornavirus and were associated with temporary reduction in lung function, but not with rejection. We also highlight a careful analysis of outcomes after pulmonary endarterectomy showing an association between the amount of material removed surgically and short-term, but not long-term, improvement in pulmonary vascular resistance;58 and a large study showing that the presence of residual DVT, right heart strain, hypotension, and hypoxia are risk factors for early (but again not late) deterioration following a pulmonary embolus.67 Observational studies can be especially interesting if the data are analysed in an innovative way. A cluster analysis of the COPD gene cohort identified potentially more informative phenotypes from a genetic point of view;68 and a study using clinician-derived multidimensional indices confirmed that the new 2011 GOLD ABCD classification of COPD is less good than the BODE index as a predictor of mortality.69 Two studies tackled the effect of obesity on the lung. An excellent physiological study showed dramatically increased oesophageal and gastric pressures, reduced FRV and ERV and markedly increased work of breathing.70 An important clinical manifestation of this is obesity hypoventilation, which Hollier et al71 showed worsened in a dose-dependent manner when treated with supplementary oxygen. Finally, observational studies come into their own when from centres dealing with rare or unfamiliar conditions. Pien et al72 showed that sleep disordered breathing in pregnancy should perhaps be in neither of these categories, as it complicates 10.5% of pregnancies in the first trimester and 26.7% in the third. Increased maternal age and Body Mass Index were predictable risk factors. Atypical carcinoid tumours sit more comfortably in the rare and unfamiliar category. Canizares et al73 provided some welcome guidance on management by showing that they were less likely to recur when treated with lobectomy and radical lymphadenectomy.
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.